Table 1.

Patient and ECMO Characteristics

Variable	All (n=35 ECMO runs)	Age ≤30 days (n=21 ECMO runs)	Age >30 days (n=14 ECMO runs)	p
Age, median (IQR)	10d (2d – 10y)	3d (1d – 9d)	11y (5m – 15y)	<0.001
Male, n(%)	16 (44)	9 (43)	10 (71)	0.096
Race
Caucasian, n(%)	16 (46)	9 (43)	7 (50)	0.538
African American, n(%)	14 (40)	9 (43)	5 (36)
Other, n(%)	5 (14)	3 (14)	2 (14)
ECMO indications, n(%)
Respiratory failure	18 (51)	17 (81)	1 (7)	<0.001
Cardiac failure	9 (26)	3 (14)	6 (43)
ECPR	7 (20)	1 (5)	6 (43)
Sepsis	1 (3)	0	1 (7)
ECMO mode
VA-ECMO	29 (83)	16 (76)	13 (93)	0.311
VV-ECMO	3 (9)	3 (14)	0
VV- to VA-ECMO	3 (9)	2 (10)	1 (7)
ECMO duration, median(IQR)	7d (3d – 14d)	12d (6d – 15d)	3.5d (1d – 5d)	0.006
Neurologic injury during ECMO, n(%)*	12 (34)	7 (33)	5 (36)	0.884
Survival to discharge, n(%)	24 (69)	18 (86)	6 (43)	0.007
Circuit clotting requiring circuit replacement, n(%)	14 (40)	12 (57)	2 (14)	0.011
Oxygenator failure, n(%)	6 (17)	5 (24)	1 (7)	0.200
ε-aminocaproic acid use, n(%)†	9 (26)	5 (24)	4 (29)	0.752
Hemorrhagic complications, n(%)
ICH	7 (20)	5 (24)	2 (14)	0.490
Pulmonary hemorrhage	7 (20)	5 (24)	2 (14)	0.490
Other (hemothorax, adrenal hemorrhage, retroperitoneal hemorrhage)	4 (11)	2 (10)	2 (14)	0.664

^*Neurologic injury during ECMO is defined as: intracranial hemorrhage, ischemic stroke, cerebral edema or brain death.

^†No antifibrinolytic agents other than ε-aminocaproic acid were used in this cohort of patients.